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ABSTRACT 
Capping protein is a heterodimer that consists of α and β subunits 
and binds to the barbed end of actin filament to prevent additional 
monomer G-actin binding and stabilize the structure of actin filament. 
One of the capping protein subunits, CAPZA2, has two putative binding 
sites for transcription factor nuclear respiratory factor-1 (NRF-1) on its 
promoter. There it may be a downstream gene of NRF-1. However, the 
regulation of CAPZA2 expression in mammalian neurons is currently 
unknown. In this study, we investigated how to regulate the expression of 
CAPZA2 gene and if NRF-1 regulates this process. To investigate the 
regulation of CAPZA2, we cloned different fragments of CAPZA2 
promoter and subjected them to promoter studies with dual-luciferase 
assays. We found that the basal promoter region is located on -42/-477 
fragment of CAPZA2 promoter and mutation of putative NRF-1 binding 
sites decreased CAPZA2 promoter activity. Furthermore, EMSA (gel 
electrophoretic mobility shift assay) showed that NRF-1 binds to these 
two putative binding sites in vitro. To further study the role of NRF-1 in 
regulating CAPZA2 expression, we cloned a series of shorter fragments 
of CAPZA2 promoter and found that NRF-1 binding sites are on the 
critical region for its expression. In addition, overexpression of full-length 
NRF-1 increased CAPZA2 promoter activity, whereas overexpression of 
dominant-negative NRF-1 decreased that. Therefore, NRF-1 is the major 
mediator in regulating CAPZA2 expression. According to these results, 
we concluded that NRF-1 binds to its putative binding sites indeed and 
regulates the expression of CAPZA2 gene.  
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中文摘要 
CapZ 為異雙體蛋白質，由α及β次單位所組成，其功能是結合到
肌動蛋白絲的 barbed end 上，以防止游離的肌動蛋白單體再結合至肌
動蛋白絲上以及防止已結合之肌動蛋白單體從上脫落，有維持肌動蛋
白絲穩定之作用。CAPZA2 屬於 capping protein 的一個次單位，在
CAPZA2 基因的啟動子上有兩個可能的 NRF-1 (Nuclear respiratory 
factor-1)的結合位，因此我們懷疑 CAPZA2 很可能是 NRF-1 轉錄因子
調控的下游基因之一。然而，目前有關 CAPZA2 在哺乳動物的神經
細胞中的調控表現仍不清楚。因此在本篇的研究中，我們將探討
CAPZA2 在細胞中是如何被調控表現且此過程是否與 NRF-1 的調控
有關。在研究啟動子的調控中，我們選殖出不同長度的 CAPZA2 啟
動子片段並且進行 Dual-luciferase 的分析。發現在啟動子-42/-477 片
段具有 CAPZA2 基本啟動子活性，若進一步將 NRF-1 的結合位做突
變之後會減少此基因啟動子之活性。另外由 EMSA 的結果證明， 
NRF-1 會結合至此基因啟動子上的兩個 NRF-1 結合位。進一步，大
量表現全長的 NRF-1 會促進 CAPZA2 啟動子之活性，反之大量表現
競爭抑制的 NRF-1 則抑制該活性，因此 NRF-1 對於調控 CAPZA2 表
現是很重要之媒介者。由以上的結果得到一個結論：NRF-1 會結合到
CAPZA2 啟動子上的兩個 NRF-1 結合位，並且調控此基因的表現。
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CHAPTER 1 
INTRODUCTION 
1-1 Introduction to capping proteins 
1-1-1 Capping proteins 
Capping protein is a heterodimer that consists of α and β subunits 
and binds to the fast growthing barbed end of actin filament at Z-line, 
preventing addition or loss of monomer G-actin binding and stabilizing 
the structure of actin filament (Casella et al., 1986). Capping protein 
locates at Z-line of actin filament also called CapZ (Casella et al., 1986; 
Casella et al., 1987). The α-subunit contains three isoforms, CAPZA1, 
CAPZA2 and CAPZA3, and β-subunits also contain three isoform, 
CAPZB1, CAPZB2 and CAPZB3 (Schafer et al., 1994). Molecular 
weights of these two subunits are about 31-36 kDa and 28-32 kDa, 
respectively (Casella et al., 1986; Casella et al., 1987). The α1 and α2 
isoforms of capping proteins were found that they are encoded by two 
different genes in chicken (Cooper et al., 1991; Hart et al., 1997). These 
two α isoforms were identified similar to each other in chicken and 
different expression levels in different mouse cells and tissues (Hart et al., 
1997). The sequences of α1and α2 isoforms reveals that vertebrates have 
two highly conserved subfamilies by phylogenetic analysis (Hart et al., 
1997). The β1and β2 isoforms are produced from a single mRNA 
transcript by alternative splicing (Schafer, et al., 1994). They are highly 
conserved in vertebrates but represent different expression levels and 
distribution (Schafer, et al., 1994). The β1 isoform was identified that it is 
enriched at Z-line and significantly expressed in muscle cells, whereas β2 
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isoform was identified enriched at intercalated line and located in the 
sarcolemma (Schafer, et al., 1994). 
The binding affinity of capping protein is mediated by two ultimate 
carboxyl-terminal 55-amino acid and 15-amino acid of the α and β 
subunits, respectively (Casella and Torres, 1994). The actin affinity of the 
α1 isoform is 40-fold higher then that of α2 isoform, whereas β1 isoform 
is similar to that of β2 isoform (Casella and Torres, 1994). 
Third α and β isoforms of capping protein, CAPZA3 and CAPZB3, 
were demonstrated that they are specifically expressed in mouse testicular 
germ cells and bull sperms, respectively (Tanaka, et al., 1994; von Bülow 
et al., 1997). In recently studies, the results revealed that CAPZA3 and 
CAPZB3 form a heterodimer and function as regulators of F-actin 
dynamics in spermatids (Geyer et al., 2009). 
1-1-2 Functions of capping proteins in neuronal differentiation 
In recently study from Davis et al., it had been shown that the β2 
subunit of capping protein, CAPZB2, regulates growth cone morphology 
and neurite outgrowth by direct interaction to β-tubulin (Davis et al., 
2009). Inhibition of CAPZB2 by RNAi in hippocampal neurons results in 
the short length of neurites and fork-like growth cones in which 
microtubules grow into the periphery zone and overlay with F-actin. The 
mechanisms of silencing CAPZB2 resulting in cytoskeletal abnormalities 
were identified (Davis et al., 2009). The in vitro experiment showed that 
CAPZB2 direct binds to β-tubulin by microtubule-interacting region and 
decreases the rate and the extent of tubulin polymerization, however, but 
not CAPZA2. In neurons, the CAPZB2 not only regulates microfilaments 
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but also microtubules and these two major cytoskeletal networks affect 
dynamics and morphology of neurite and growth cones. This study 
suggested that CAPZB2 possible plays a key role of the assembly of 
microfilaments and microtubules (Davis et al., 2009). 
1-2 CAPZA2 
CAPZA2 belongs to F-actin capping protein α subunit family and its 
gene locates in chromosome 7q31.2-q31.3 (Barron-Casella., 1995). 
According to bioinformatic search, there are two putative transcription 
factor nuclear respiratory factor-1 (NRF-1) binding sites on its promoter. 
Thus CAPZA2 may be a NRF-1 downstream gene. Few studies focus on 
the functions of CAPZA2, especially in neurons. In a recent report, it 
suggested that CAPZA2 may not involve in tubulin polymerization during 
grown cone development (Davis et al., 2009). However, the functions and 
regulation of CAPZA2 in mammalian neurons is currently unknown. 
1-3 NRF-1 
1-3-1 Structure and functions of NRF-1 
 NRF-1 belongs to a member of nuclear transcription factor family 
that contains a putative basic leucine zipper DNA-binding, dimerization, 
and nuclear localization signal domain in N-terminus and a transcriptional 
activation domain which consists of hydrophilic amino acid residues in 
C-terminus (Virbasius et al., 1993; Efiok et al., 1994). NRF-1 was first 
found that functions in regulating eukaryotic initiation factor 2α (eIF-2α) 
gene expression (Jacob et al., 1989). It has been shown that NRF-1 
formed a heterodimer binding to GC-rich palindromic sequences, which 
sequences usually are (C/T)GCGCA(C/T)GCGC(G/A) (Jacob et al., 
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1989).  
NRF-1 is a transcription factor that binds to promoters of 
downstream genes and then activates genes expression and usually forms 
a homodimer to activate nuclear genes including mitochondrial proteins 
relative to mitochondrial biogenesis and function (Scarpulla, 2008). The 
mitochondrial genes encoded in cell nucleus, such as ATP synthase, 
cytochrome c, cytochrome c oxidase subunit IV, and mitochondrial 
transcription factor A (Tfam) (Evans and Scarpulla, 1990; Scarpulla et al., 
2006; Virbasius and Scarpulla, 1994). Tfam is a key transcriptional 
activator of the mitochondria that activates mitochondrial DNA 
replication and transcription. In addition, NRF-1 also be identified that 
involves in other fundamental cellular functions, such as protein 
translation/turnover, DNA synthesis/repair, and cell proliferation (Efiok et 
al., 1994; Efiok and Safer, 2000). 
1-3-2 Role of NRF-1 in neurite outgrowth 
 Our previous study had shown a novel function of NRF-1 in neuronal 
differentiation (Chang et al., 2005). In human neuroblastoma IMR-32 
cells, stable or transient expression of full-length NRF-1 not only induced 
neurite outgrowth but also increased the length of neurite, whereas 
expression of dominant-negative of NRF-1 inhibited the induction and 
extension of neuritis in medium containing 10% fetal bovine serum or not. 
In primary mouse cortical neurons, transient expression of full-length 
NRF-1 also induced neurite outgrowth and increased the length of neurite 
but not dominant-negative NRF-1. These results demonstrated that NRF-1 
involves in neurite outgrowth (Chang et al., 2005). 
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1-3-3 NRF-1-increased neurite outgrowth mediated by its 
downstream genes 
 Recently it has demonstrated that NRF-1 is a critical role in 
regulating integrin-associated protein (IAP or CD47) and synapsin I 
promoter activity (Chang and Huang, 2004; Wang et al., 2009). Mutation 
of NRF-1 binding site on IAP promoter by deletion mutation or 
site-directed mutagenesis significantly decreased the promoter activity of 
IAP gene. These suggested that the NRF-1 site is important to IAP 
promoter activity. Transient overexpression of full-length NRF-1 
significantly increased the IAP promoter activity, whereas overexpression 
of dominant-negative of NRF-1 significantly decreased the IAP promoter 
activity (Chang and Huang, 2004). Moreover, NRF-1 increases neurite 
outgrowth and this effect is through its downstream gene IAP (Chang et 
al., 2005). Knock down of the IAP gene by antisense cDNA and 
cotransfected with full-length NRF-1 into neuroblastoma cells alter the 
growth of neurotes. These results demonstrated that the NRF-1 regulates 
IAP promoter and involves in neurite outgrowth through this gene (Chang 
et al., 2005). In addition to IAP, our previous study also showed that 
another downstream gene synapsin I mediates NRF-1-regulated neurite 
outgrowth (Wang et al., 2009). 
1-4 PGC-1 
1-4-1 PGC-1 family 
PGC-1α, PGC-1β and PGC-related coactivator (PRC) belong to 
PGC-1 family that play roles in transcriptional coactivation. These three 
proteins are homology to each other. The N-terminus contains a 
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transcriptional activation domain and the leucine-rich nuclear hormone 
receptor-interacting motif (LXXLL or LLXXL), and the C-terminus 
contain an RNA-recognition domain in all three PGC-1 family members 
(Kressler et al., 2002; Lin et al., 2002; Andersson and Scarpulla, 2001). In 
addition, specific shared domain of PGC-1α and PGC-1β is the central 
region and those of PGC-1α and PRC are proline-rich and 
serine-arginine-rich (RS) domains (Lin et al., 2005; Kelly and Scarpulla, 
2004). The PGC-1α protein has several functional domains able to 
interact with specific target transcription factors, including nuclear 
receptors, NRF-1, MEF2, and FOXO1. In addition, it also has a MAPK 
phosphorylation (P) sites (Finck and Kelly, 2006). 
1-4-2 NRF-1 activation by PGC-1 co-activator 
Previous studies have identified many co-factors, such as PGC-1 
family, which interact with NRF-1 and activate transcription (Andersson 
and Scarpulla, 2001; Wu et al., 1999). It has been shown that ectopic 
overexpression of PGC-1 increased nuclear and mitochondrial genes and 
many of these genes are directly or indirectly regulated by NRF-1 or 
NRF-2 expression in NIH 3T3 and the myogenic cell line C2C12 cells 
(Wu et al., 1999; Scarpulla et al., 2006). Moreover, overexpression of 
PGC-1 increases mRNA levels of NRF-1 and NRF-2 and PGC-1 interacts 
with NRF-1 to increase transcriptional activation of NRF-1 downstream 
genes (Wu et al., 1999). Furthermore, the PGC-1-mediated increase in 
mitochondrial biogenesis is inhibited by expression of dominant-negative 
NRF-1 (Wu et al., 1999). 
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1-4-3 Functions of PGC-1 in neurons 
 A previous study has showed that PGC-1α was significantly 
expressed in the regions of mouse brain, including striatum, cerebral 
cortex, globus pallidus, hippocampus, and substantial nigra, which are 
idenfied by in situ hybridization (Tritos et al., 2003). But its functional 
role in the brain remains to be investigated. 
However, the later study identified that PGC-1α is important to 
maintain normal function of brain (Lin et al., 2004). In PGC-1α null mice, 
it has been found that hyperactivity and behavioral changes lead to 
neuronal degeneration in the specific brain area, the striatum, and it plays 
a key role in motor coordination (Lin et al., 2004). It also been shown that 
PGC-1α is a critical role in regulating the mitochondrial gene expression. 
According to this study, authors proposed that PGC-1α may play a role in 
regulating the neuronal gene expression and function, because the brain- 
specific genes which not involve in mitochondrial function were 
decreased in PGC-1α null mice (Lin et al., 2004). In addition, it has been 
shown that neurite growth is significantly reduced in PGC-1α null mice 
compared to wild type animals, which display normal neurite outgrowth 
and complex network in primary striatal neurons (Lin et al., 2004). In our 
unpublished result, we also found that overexpression of PGC-1 increases 
neurite outgrowth in human neuroblastoma IMR-32 cells.  
1-5 Specific aims 
The specific aims of this study are divided into two parts: 
1. To understand the regulation of CAPZA2 expression. 
2. To investigate if CAPZA2 involves in neuronal differentiation. 
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CHAPTER 2 
MATERIALS AND METHODS 
2-1 Cell culture 
 Human neuroblastoma IMR-32 (CCRC 60014) and hepatoma HepG2 
(CCRC 60048) cell lines were purchased from Culture Collection and 
Research Center, Food Industry and Development Institute, Hsinchu, 
Taiwan. Cells were grown in minimum essential medium Eagle with 
Earle’s salt base (Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
fetal bovine serum (HyClone, Logan, UT) in a humidified atmosphere 
containing 5% CO2 at 37 °C. 
2-2 Plasmid constructs 
pGL3-Basic and pRL-TK luciferase reporter vectors (Promega, 
Madison, WI) were used for CAPZA2 promoter reporter assays. The 
promoter constructs of the CAPZA2 gene were generated by PCR 
amplification of a 1328-bp fragment that was then inserted into the 
pGL3-Basic vector (Promega). The resulting plasmid was named 
pGL3-1328 construct. Different restriction enzyme-digested fragments 
from CAPZA2 were then ligated into pGL3-Basic to create a series of 
human CAPZA2 promoter constructs, including pGL3-1328, pGL3-956, 
and pGL3-477. Another series of human CAPZA2 promoter constructs 
containing shorter fragments in pGL3-Basic vectors, including pGL3-202, 
pGL3-180, pGL3-141, and pGL3-119, were similarly made by using 
differential forward primers on the CAPZA2 promoter with the KpnI site 
at the 5’-end and a same reverse primer (pr1) with the XhoI site at the 
3’-end on CAPZA2 promoter fragments. These fragments were then 
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digested by KpnI and XhoI and inserted into pGL3-Basic (Table 1 and 
Fig. 1A). Promoter constructs containing nucleotide substitutions in the 
sequence motifs of NRF-1 sites were individually generated by PCR 
amplification with primer pairs spanning the mutant nucleotides 
according to the protocol of site-directed mutagenesis (Stratagene, La 
Jolla, CA). The plasmids pGL3-477M1, pGL3-477M2, and 
pGL3-477M1+2 were constructed in the backbone of pGL3-477 using 
primer pairs containing the introduced mutations. The trans element 
CGCGCACGCGCA and cis element TGCGCGTGCGCG were mutated 
to CGCAAACGCAAA (pGL3-477M1) and TTTGCGTTTGCG 
(pGL3-477M2), respectively. In addition to mutating a single NRF-1 
binding site, pGL3-477M1+2 is another construct with double mutations 
on both NRF-1 binding sites. 
For the GFP-expressing constructs, pCMS-EGFP (Clontech, BD 
Biosciences, Palo Alto, CA) was used as the vector. For the construction 
of CAPZA2 cDNA expression vector (pCMS-CAPZA2), CAPZA2 
cDNA was amplified using the primer pair cf1 (5’- CGG TTT GTC GCC 
AGA AGG AAG AT) and cr1 (5’- AAC GCA AAG ACA CTA AAA 
TGA TC), digested with NheI and NotI, and inserted to pCMS-EGFP 
vector. The cloning of full-length and dominant-negative NRF-1s was 
described as our previous report (Chang and Huang, 2004). The NRF-1 
and CAPZA2 cDNAs were under the control of CMV promoter and the 
GFP cDNA was under the control of SV40 promoter. 
2-3 Transient transfection 
Transient transfection was carried out by the calcium phosphate 
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precipitation method (Jordan et al., 1996). For luciferase assays, IMR-32 
and HepG2 cells (2.0 × 105) were seeded in each well of six-well plates 
and cultured in 2 or 2.5 ml of medium. The pGL-3 vectors containing 
CAPZA2 promoter fragments and the plasmid pRL-TK were transfected 
to cells for reporter assays. The plasmid pRL-TK was cotransfected to 
normalize the transfection efficiency. Plasmids were mixed with 5 µl of 
2.5 M calcium chloride in volume of 50 µl containing 0.1 × TE buffer. 
The mixture was then mixed with one volume of 2× HEPES buffer (140 
mM NaCl, 1.5 mM Na2HPO4．2H2O, and 50 mM HEPES; Adjusted pH to 
7.05) and incubated for 1 min at room temperature. The mixture was 
added to the cells for transfection. After 14-16 h of transfection, the 
medium was exchanged with fresh medium and the cells were grown for 
further assays. 
 For neurite measurement, the plasmids pCMS-EGFP, 
pCMS-CAPZA2 and pCMS-NRF-1 were transfected into IMR-32 cell 
lines using the same procedure for transient transfection of the reporter 
plasmids. Cells (1.5 × 105) were cultured on 3-cm dishes for 24 h. Then, 
the medium was exchanged with 2 ml of fresh medium, and cells were 
incubated for additional 1 h for the subsequent transfection. After 
transient transfection, the cells were incubated for 24, 48 or 72 h for 
measurement of neurite length. 
2-4 Dual-luciferase assay 
After transfection and subsequent incubation, the cells were washed 
in phosphate-buffered saline (137 mM sodium chloride, 2.7 mM 
potassium chloride, 10 mM dibasic sodium phosphate, and 2 mM 
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monobasic potassium phosphate) and the lysates were prepared by 
scraping the cells from plates in the presence of 1 × passive lysis buffer 
(Promega). Luciferase assays were performed using Dual-Luciferase 
Assay System (Promega) and a Sirius luminometer (Berthold Detection 
System, Pforzheim, Germany). 
2-5 Preparation of nuclear extracts 
IMR-32 cells (1 × 106) were plated onto 10-cm culture dishes and 
incubated for 2 days. The cells were washed with 2 ml of 
phosphate-buffered saline and collected in 1 ml of the same buffer. The 
cells were centrifuged at 2,000 × g for 2 min, and the supernatant was 
discarded. The cell pellet was incubated in 400 µl of buffer A (10 mM 
HEPES (pH 7.9), 1.5 mM magnesium chloride, 10 mM potassium 
chloride, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 2 
µg/ml leupeptin, 10 µg/ml aprotinin, 50 mM sodium fluoride, and 1 mM 
sodium orthovanadate) on ice for 10 min and then gently shaken for 10 s. 
The pellet of the crude nuclei was collected by centrifugation at 12,000 × 
g for 10 s. The pellet was resuspended in 3 volumes of buffer C (20 mM 
HEPES (pH 7.9), 25% glycerol, 420 mM sodium chloride, 1.5 mM 
magnesium chloride, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl 
fluoride, 0.5 mM dithiothreitol, 2 µg/ml leupeptin, 10 µg/ml aprotinin, 50 
mM sodium fluoride, and 1 mM sodium orthovanadate) by vortex for 15 s, 
and then incubated on ice for 20 min. After centrifugation at 12,000 × g 
for 2 min, the supernatant containing the nuclear proteins was collected, 
quantified with BCA Protein Assay Reagent (Pierce, Rockford, IL), and 
stored at -70 °C in aliquots. 
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2-6 Gel electrophoretic mobility shift assays (EMSA) 
The EMSA used the following oligonucleotides: CAPZA2 NRF-1 
(f-1), 5’- GCGCC CGCGC ACGCG CACAG C-3’; CAPZA2 NRF-1 
(r-1), 3’- GGCTG TGCGC GTGCG CGGGC G-5’. CAPZA2 NRF-1 (f-2), 
5’- CGGGG TGCGC GTGCG CGGCG G-3’; CAPZA2 NRF-1 (r-2), 3’- 
GCCGC CGCGC ACGCG CACCC-5’. 30 pmol of each of the forward 
and reverse oligonucleotides placed in a volume of 23 µl of 1× Klenow 
(DNA polymerase) buffer were heated at 94 °C for 2 min and annealed at 
room temperature for at least 30 min. The annealed double-stranded 
oligonucleotides were end-labeled by a fill-in reaction using DNA 
polymerase (Klenow) (Promega). One unit of the DNA polymerase and 
40 µCi of [α-32P]dCTP (PerkinElmer, Boston, MA) were added into the 
annealed oligonucleotides and the mixture was incubated at 30 °C for 15 
min. The labeled oligonucleotides were purified by Sephadex G-50 
columns (GE Healthcare, Buckinghamshire, UK). The DNA binding 
reaction was conducted at 4 °C for 30 min in a mixture containing 3 µg of 
nuclear extract, 10 mM Tris-Cl (pH 7.5), 50 mM sodium chloride, 0.5 
mM dithiothreitol, 0.5 mM EDTA, 1 mM magnesium chloride, 4% 
glycerol, 0.05 µg poly(dI-dC)．poly(dI-dC) (GE Healthcare) and 2 × 104 
cpm of 32P-labeled double-stranded oligonucleotides for 30 min. In 
supershift assays, antibodies were incubated with the reaction mixture at 4 
°C for 2 h before the addition of the CAPZA2 NRF-1 probes. The NRF-1 
and NF-κB antibodies were from Abcam (Cambridge, MA) and Santa 
Cruz Biotechnology (Santa Cruz, CA), respectively. The normal goat 
 - 13 -
serum was from Vector Laboratories (Burlingame, CA). The 
DNA-protein complexes were analyzed on a 4% polyacrylamide gel 
(acrylamide/bisacrylamide 29:1 in 0.5 × Tris borate-EDTA buffer) at 10 
V/cm for 2 h. The gel was analyzed by autoradiography. 
2-7 RNA isolation and reverse transcription (RT)-polymerase chain 
reaction (PCR) 
To understand endogenous CAPZA2 expression level in different 
cells, the RNA was isolated from IMR-32 and HepG2 cells. IMR-32 and 
HepG2 cells (1 × 106) were plated onto 4-cm culture dishes and incubated 
for 2 days. TRIzol reagent (Invitrogen, Carlsbad, CA) was used to isolate 
total RNA following manufacturer’s instructions. DNase treatment was 
used to remove DNA contamination (Promega). Reverse transcription 
was performed using 1 µg RNA, random hexamer primer, dNTP and 
M-MLV reverse transcriptase (H-) (Promega) in reaction solution 
containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2 and 10 
mM DTT. The cDNA was amplified by PCR using forward primer: 5’- 
CGGTT TGTCG CCAGA AGGAA GAT-3’, and reverse primer: 5’- 
AACGC AAAGA CACTA AAATG ATC-3’. The PCR program was: 95 
°C for 10 min, 95 °C for 20 sec, 55 °C for 30 sec, 72 °C for 34 sec, for 32 
cycles, 72 °C for 7 min. 
RT-PCR was also used to confirm if exogenous full-length and 
dominant-negative NRF-1s were expressed. Full-length and 
dominant-negative NRF-1 reverse transcription was performed using 1 
and 0.75 µg RNA, respectively. The exogenous full-length NRF-1 was 
amplified by PCR using forward primer: 5’-GAGTC CAAG A TGCTA 
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ATG-3’, and reverse primer located in vector: 5’-TAGAA GGCA 
CAGTC GAGG-3’. The exogenous dominant-negative NRF-1 was 
amplified using forward primer: 5’-GGAGA ATGTG GTGCG TAA-3’, 
and reverse primer: 5’-TAGAA GGCA CAGTC GAGG-3’. The PCR 
program was: 95 °C for 10 min, 95 °C for 15 sec, 48 °C for 15 sec, 72 °C 
for 15 sec, for 30 cycles, 72 °C for 7 min. The PCR products were 
analyzed by 2.4% agarose gel electrophoresis in 0.5 X TBE solution and 
visualized by staining with ethidium bromide under UV light. 
2-8 Measurement of neurite outgrowth 
Induction of neurite outgrowth was examined by measuring the 
percentage of neurite-bearing cells. GFP-positive cells were observed 
under the fluorescent microscope (Olympus, Tokyo, JP). The length of 
the longest process for each of >100 cells was determined for each sample 
using Metamorph Software (Universal Imaging Corporation, 
Downingtown, PA). A process, which is longer than 25 µm in IMR-32 
cells, is defined as a neurite. The cell numbers with various neurite 
lengths were measured and plotted in the curve as percentages of 
neurite-bearing cells. 
2-9 Statistics 
The relative activity of different reporter constructs and percentages 
of neurite-bearing cells were compared. Statistical analysis was 
performed by unpaired Student’s t test for pairwise comparisons. A p 
value <0.05 was regarded as significant. 
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CHAPTER 3 
RESULTS 
3-1 The basal promoter activity of CAPZA2 is located at –42 to –477 
To determine the boundaries of a minimal CAPZA2 promoter region 
and identify cis elements that regulate the expression of CAPZA2, a 
series of 5’-CAPZA2 promoter deletion constructs were generated and 
transfected into IMR-32 and HepG2 cells. All plasmid constructs were 
defined relative to the translational initiation codon (Fig. 1B). Firstly, we 
confirmed CAPZA2 were expressed in these two cells and found the 
CAPZA2 expression levels in HepG2 cells are much higher than that in 
IMR-32 cells (Fig. 1A). The reporter constructs were cotransfected into 
IMR-32 and HepG2 cells with an internal control Renilla luciferase 
vector (pRL-TK). The firefly luciferase activity of each reporter was 
normalized with the internal control to correct transfection efficiency. 
Results were represented as an increase in activity with respect to that of 
the pGL3-Basic vector or the relative activity compared with that of the 
-477 construct (Fig. 1C and 1D). 
 In IMR-32 cells, the shortest reporter that still retained the basal 
promoter activity was the -477 construct, whereas deletion for another 
297 bp (the -180 construct), 336 bp (the -141 construct), or 358 bp (the 
-119 construct) resulted in markedly loss of reporter activity. Addition of 
275 bp to the -202 construct generated the -477 construct and increased 
the reporter activity by about 50 %. In the construct containing additional 
479 bp (the -956 construct) and in the longest construct (the -1328 
construct), the promoter activity was not increased (Fig. 1C). A similar 
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pattern of promoter activity was observed when the reporter constructs 
were transfected into HepG2 cells, but with four exceptions (Fig. 1D). 
First, overall promoter strength pattern relative to pGL3-Basic is similar 
to that in HepG2 cells, but the promoter strength of -202, -180, -141 and 
-119 promoter fragment relative to pGL3-Basic was much higher in 
HepG2 cells, about 3, 13, 48, and 12-fold compared with IMR-32 cells, 
respectively. Second, the constructs of -477, -956 and -1328 produced 
maximal activity in IMR-32 cells; in HepG2 cells, however, the construct 
of -202 produced maximal activity. Third, the reporter activity decreased 
to the -202 construct promoter activity level in the construct containing 
additional 275 bp (the -477 construct), 479 bp (the -956 construct) and in 
the longest construct (the -1328 construct). Fourth, there were negative 
regulators located between -202 and -477 in IMR-32 cells; in HepG2 cells, 
however, there may be positive regulators located between -202 and -477 
(Fig. 1D). Results suggested a core promoter of the human CAPZA2 gene 
located between -477 and -42 upstream of the translational initiation 
codon in both IMR-32 cells and HepG2 cells. 
 The sequence from -477 to ATG was searched for homology to 
previously described regulatory elements in several databases. There are 
many putative binding sites for transcription factor in this region (Fig. 2), 
including activating enhancer binding protein 2 (AP-2), transcription 
factor Sp1, and nuclear respiratory factor 1 (NRF-1). 
3-2 Mutation of NRF-1 sites decreases CAPZA2 basal promoter 
activity 
To identify important transcription factor binding sites on CAPZA2 
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promoter, the point mutation constructs were generated by site-directed 
mutagenesis. As shown in Fig. 3, the region from -477 to -42 consists of a 
GC-rich sequence that includes the putative AP-2, Sp1 and NRF-1 sites. 
First, point mutations were introduced into NRF-1 sites to determine 
whether NRF-1 sites were necessary for CAPZA2 promoter activity. The 
two putative NRF-1 sites in the CAPZA2 promoter are two 12-base 
tandem-repeat sequences, TGCGCGTGCGCG and CGCGCACGCGCA, 
respectively. When two bases in each of the repeat sequences were 
replaced by two T or A residues to generate the pGL3-477M1 and 
pGL3-477M2 constructs, a 75% decrease in promoter activity was 
observed in IMR-32 cells (Fig. 3A). Further, mutation of both putative 
NRF-1 sites of CAPZA2 promoter, simultaneously, generates the 
pGL3-477M1+2 construct; however, the promoter activity was markedly 
reduced by 95% (Fig. 3A). A similar pattern of promoter activity was 
observed when the reporter constructs were transfected into HepG2 cells 
(Fig. 3B). But the pGL3-477M1, pGL3-477M2 and pGL3-477M1+2 
promoter strength relative to -477 (wild type) was much higher in HepG2 
cells, about 4 to 6-fold compared with IMR-32 cells. The levels of 
pGL3-477M1, pGL3-477M2 and pGL3-477M1+2 promoter activity were 
decreased by16, 39 and 87% compared with -477 (wild type) in HepG2 
cells. According to these results, the NRF-1 sites of CAPZA2 promoter 
may be tissue-specific. These results suggested that the consensus NRF-1 
sites are functional regulatory elements on the CAPZA2 promoter in both 
IMR-32 and HepG2 cells. 
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3-3 NRF-1 binds to NRF-1 elements on CAPZA2 promoter 
To investigate whether the NRF-1 protein binds to the two putative 
NRF-1 elements on CAPZA2 promoter, the EMSA experiments were 
performed. Nuclear extracts from IMR-32 cells were mixed with 
32P-fill-in-labeled double-stranded oligonucleotides in vitro. A major band 
of DNA-protein complex was found in all lanes when the nuclear extracts 
were incubated with the wild-type CAPZA2 NRF-1 probes (Fig. 4, lanes 
2-5 and lanes 7-10). No band was found when nuclear extracts were not 
added into the probes (Fig. 4, lanes 1 and 6). Supershift assays using the 
anti-NRF-1 antiserum were used to further confirm the binding of the 
NRF-1 on its DNA elements and bands were supershifted indeed (Fig. 4, 
lanes 3 and 8). However, the NF-κB antibody did not generate any 
supershifted band (Fig. 4, lanes 4 and 9), neither did the normal goat 
serum (Fig. 4, lane 5 and 10). These results strongly suggested that 
NRF-1 binds to these two putative NRF-1 elements on the CAPZA2 
promoter. 
3-4 Overexpression of NRF-1 increases CAPZA2 promoter activity 
but dominant-negative NRF-1 decreases promoter activity 
If the NRF-1 protein binds to the NRF-1 elements on the CAPZA2 
promoter in vitro, it should functionally regulate the promoter activity of 
the CAPZA2 gene in vivo. To study this possibility, the full-length or 
dominant-negative NRF-1 cDNAs were cotransfected with the reporter 
construct -477 (wild type) into IMR-32 and HepG2 cells and the 
luciferase activity was measured. The full-length NRF-1 contains 
complete NRF-1 protein structure but the dominant-negative mutant of 
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NRF-1 contains only the N-terminal DNA binding domain and lacks 
transactivation domain, which can bind to its responsive element (Chang 
and Huang, 2004). Firstly, to confirm exogenous full-length and 
dominant-negative NRF-1 was expressed in cells by RT-PCR. No band 
was found in control groups which did not overexpress NRF-1s (Fig. 5, 
left panel, lanes 1-2, and right panel, lanes 1-2). When overexpressing 
full-length or dominant-negative NRF-1, the exogenous NRF-1s were 
detected in a dose-dependent manner (Fig. 5 left panel, lanes 3-6, and 
right panel, lanes 3-6). However, it can not initiate gene transcription 
when binding to promoter, showing a competitive inhibition. As shown in 
Fig. 5B, overexpression of full-length NRF-1 significantly increased the 
CAPZA2 promoter activity in a dose-dependent manner. At the highest 
dose (1 µg), the promoter activity of the reporter construct increased up to 
14-fold as compared with control in IMR-32 cells. A similar induction 
pattern of promoter activity was observed in HepG2 cells. However, the 
promoter activity increased about 1.4-fold at the highest dose in HepG2 
cells (Fig. 5C), suggesting a more potent effect of NRF-1 for inducing 
expression of this gene in IMR-32 cells. In contrast, overexpression of 
dominant-negative NRF-1 significantly reduced the CAPZA2 promoter 
activity in both cell lines as compared with the mock controls. At the 
highest dose (1 µg), the promoter activity of the reporter construct was 
reduced markedly up to 60% in IMR-32 cells (Fig. 6A). A similar 
decreased pattern of promoter activity was observed in HepG2 cells. At 
highest dose, the promoter activity decreased markedly up to 60-70% (Fig. 
6B). In Fig. 5 and 6, the relative activity was represented as the 
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percentage of firefly luciferase activity of mock control but not 
normalized with the Renilla luciferase activity, because the full-length 
and dominant-negative NRF-1 could enhance the activity of the Renilla 
luciferase by unknown or non-specific effects (Chang and Huang, 2004). 
These results confirm that NRF-1 interacts with CAPZA2 promoter and 
regulates its downstream gene expression in vivo. 
3-5 Mutation of both pGL3-477M1 and pGL3-477M2 sites influences 
NRF-1-induced CAPZA2 promoter activity but not that of 
pGL3-477M1 and pGL3-477M2 alone 
It has been shown that NRF-1 functionally regulates the promoter 
activity of CAPZA2 gene in vivo. To further confirm these results, the 
full-length or dominant-negative NRF-1 constructs were cotransfected 
with the reporter constructs pGL3-477M1, pGL3-477M2 and 
pGL3-477M1+2 into IMR-32 and HepG2 cells, and the luciferase activity 
was measured. As shown in Fig. 7, overexpression of full-length NRF-1 
significantly increased the activity of single and double mutations of 
CAPZA2 promoter in both cell lines, as compared with cells not 
overexpressing full-length NRF-1. When overexpressing NRF-1, the 
differences of promoter activity between the construct -477 (wild type) 
and pGL3-477M1 or pGL3-477M2 are not significant, suggesting single 
NRF-1 sites is sufficient to express downstream gene at high levels of 
NRF-1 (Fig. 7A and B, upper and middle panels). Although, 
overexpression of full-length NRF-1 increased the promoter activity of 
double mutant construct in both cell lines, the activity was much lower 
than that of the wild type group overexpressing full-length NRF-1 in 
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IMR-32 (Fig. 7A, lower panel) but not in HepG2 cells (Fig. 7B, lower 
panel), suggesting a cell-specific effect of NRF-1 expression. 
3-6 Dominant-negative NRF-1 further decreases promoter activity of 
single mutation of CAPZA2 gene but not that of double mutation 
In contrast to overexpresion of full-length NRF-1, overexpression of 
dominant-negative NRF-1 further reduced promoter activity of single 
mutation of CAPZA2 gene in both cell lines, as compared with the mock 
controls (Fig. 8). After transfection of 100 ng plasmid, the promoter 
activity of the pGL3-477M1 and pGL3-477M2 reporter construct was 
reduced markedly up to 50 and 65% in IMR-32 and HepG2 cells, 
respectively. However, dominant-negative NRF-1 did not further decrease 
promoter activity of double mutation of CAPZA2 promoter in IMR-32 
cells (Fig. 8A, lower panel). In addition, it showed an increase of 
promoter activity of double mutant construct in HepG2 cells, suggesting a 
non-specific effect of dominant-negative NRF-1 (Fig. 8B, lower panel). 
In this experiment, results showed that one normal NRF-1 element is still 
able to drive CAPZA2 gene transcription when mutating single NRF-1 
element on its promoter, but this ability disappears when mutating two 
NRF-1 elements. These results further confirm that NRF-1 interacts with 
CAPZA2 promoter and regulates CAPZA2 gene expression in vivo. 
3-7 Overexpression of PGC-1 increases CAPZA2 promoter activity 
It has been known that PGC-1 is one of the upstream molecules of 
NRF-1 and plays an important role in NRF-1 transactivation (Scarpulla, 
2008). Therefore, we were interested if PGC-1 can involve in expression 
of NRF-1 downstream genes. To identify whether PGC-1 regulates 
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CAPZA2 promoter activity, the PGC-1 cDNA was cotransfected with the 
reporter construct -477 (wild type) into IMR-32 and HepG2 cells, and the 
luciferase activity was measured. As shown in Fig. 9, overexpression of 
PGC-1 significantly increased the CAPZA2 promoter activity in a 
dose-dependent manner in both cell lines, as compared with the mock 
controls. At highest dose (1 µg), the promoter activity of the reporter 
construct increased up to 3.8-fold in IMR-32 cells (Fig. 9A). A similar 
pattern was observed in HepG2 cells and the promoter activity of the 
reporter construct increased up to 2.1-fold when transfecting the highest 
dose of PGC-1 cDNA (1 µg) (Fig. 9B). In Fig. 9, the relative activity was 
represented as the percentage of firefly luciferase activity of mock control 
but not normalized with the Renilla luciferase activity, because the PGC-1 
could enhance the activity of the Renilla luciferase by unknown effects. 
These results showed that PGC-1 may regulate CAPZA2 gene expression 
in vivo. 
3-8 Mutation of putative NRF-1 binding sites influences 
PGC-1-induced CAPZA2 promoter activity 
To further confirm PGC-1 functionally regulates the promoter activity 
of the CAPZA2 gene in vivo, the PGC-1 cDNA was cotransfected with the 
mutant reporter constructs into IMR-32 and HepG2 cells, and the 
luciferase activity was measured. Overexpression of PGC-1 significantly 
increased the promoter activity of single and double mutant constructs in 
both cell lines, as compared with controls which did not overexpressed 
PGC-1 (Fig. 10). Although overexpression of PGC-1 increased the double 
mutant CAPZA2 promoter activity as compared with the 
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non-overexpressed mutant groups, the promoter activity was much lower 
than that of wild type groups (Fig. 10A and B, lower panels). These 
results further confirmed that PGC-1 regulates NRF-1 downstream 
CAPZA2 gene expression in vivo. 
3-9 CAPZA2 may not involve in neurite outgrowth 
In human neuroblastoma IMR-32 cells and mouse primary cortical 
neurons, transient overexpression of NRF-1 enhances neurite outgrowth. 
This effect is through its downstream gene IAP (Chang at al., 2005). We 
are interested whether CAPZA2 is involved in neurite outgrowth. To 
investigate the function of CAPZA2 in neurons, we transiently introduced 
the CAPZA2-GFP construct into human neuroblastoma IMR-32 cells and 
measure the percentage of neurite-bearing cells. The transfectants were 
visualized as GFP-positive cells under the fluorescent microscope. The 
percentage of cells bearing neurites (over 25 µm in neurite length) was 
used to measure the induction of neurites. The percentage of 
neurite-bearing cells transfected with CAPZA2 was not significantly 
changed compared with control pCMS-EGFP (Fig. 11). The 
pCMS-NRF-1 was as a positive control. These results revealed that 
CAPZA2 may not induced neurite outgrowth in human neuroblastoma 
IMR-32 cells. 
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CHAPTER 4 
DISCUSSION 
4-1 NRF-1 and PGC-1 regulates CAPZA2 gene promoter 
In this study, we investigated the regulation of CAPZA2 expression 
by NRF-1 in several part of evidence. First, site-directed mutagenesis of 
the two NRF-1 elements decreased CAPZA2 promoter activity. Second, 
supershift assays of EMSA experiment showed that NRF-1 specifically 
bound to the two NRF-1 elements in the human CAPZA2 promoter in 
vitro. Third, overexpression of NRF-1increased CAPZA2 promoter 
activity in human neuroblastoma IMR-32 and HepG2 cells, and 
overexpression of dominant-negative NRF-1 decreased CAPZA2 
promoter activity in human neuroblastoma IMR-32 and HepG2 cells. In 
addition, we also found NRF-1 upstream coactivator PGC-1 increased the 
promoter activity of CAPZA2 gene by overexpression of PGC-1. Together, 
we have shown that NRF-1 and PGC-1 are positively regulators to human 
CAPZA2 gene.  
To understand if NRF-1 regulates CAPZA2 expression in vivo, more 
functional assays must be carried out. In our previous report, serum 
starvation induces NRF-1 binding activity (Wang et al., 2009). Therefore, 
it may be a cellular model to induce NRF-1 activity. In addition, usage of 
transgenic strategies, such as overexpression of functional NRF-1 via 
gene transfer by viral vectors, is powerful and popular to elucidate 
whether induction of NRF-1 will increase CAPZA2 expression. In 
contrast, inhibition of NRF-1 by shNRF-1 will be another useful tool to 
address this issue. Data from these experiments will connect the 
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relationship between NRF-1 and CAPZA2 expression. Another 
interesting issue is the location of transcriptional start site on CAPZA2 
gene. Rapid amplification of 5’ complementary DNA ends (5’ RACE) 
may be subjected to determine it. 
In our previous study, we found that overexpression of NRF-1 may 
increase the promoter activity of Renilla TK gene via non-specific effects 
(Chang and Huang, 2004). In this study, we found the similar results in 
overexpresion of both full-length and dominant-negative NRF-1s. We 
propose that it is a non-specific effect too. To clarify this issue, 
measurement of mRNA levels of luciferases and CAPZA2 by RT-PCR or 
real-time PCR directly may be a possible strategy.  
4-2 One NRF-1 site is sufficient to drive CAPZA2 expression 
Based on previous bioinformatic search, we discover two NRF-1 
elements on CAPZA2 promoter. However, we did not know whether 
single or both of NRF-1 elements are sufficient to regulate CAPZA2 
promoter activity. Results showed that single mutation of NRF-1 element 
decreased the CAPZA2 promoter about 20-70% and mutation of both 
NRF-1 elements dramatically decreased promoter activity more than 90% 
as compared with wild type promoter (Fig. 3). Interestingly, 
overexpression of full-length or dominant-negative NRF-1s can affect 
promoter activity of single mutant constructs but less affect that of double 
mutant construct in IMR-32 cells (Fig. 7, 8 and 10). These results also 
confirm the importance of NRF-1 on CAPZA2 promoter and suggest that 
single NRF-1 site can maintain the basal expression levels of this gene. 
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4-3 NRF-1 regulates CAPZA2 promoter in a cell-specific manner  
In this study, deletion constructs and site-directed mutations of 
NRF-1 sites decreased the CAPZA2 promoter activity in IMR-32 and 
HepG2 cells. In IMR-32 cells, deletion, single and double point mutations 
of NRF-1 sites decreased the CAPZA2 promoter activity about 90% and 
75%, and 95% of promoter activity, respectively (Fig. 1C and 3A). 
However, in HepG2 cells, the CAPZA2 promoter activity was decreased 
about 80% by deletion mutation the first NRF-1 site, and about 90% by 
deletion mutation of the second NRF-1 site (Fig. 1D). However, single 
point mutation of first and second sites decreased only about 20% and 
40% of CAPZA2 promoter activity, respectively and double mutations 
decreased about 80% of promoter activity in HepG2 cells (Fig. 3B). In 
addition, changed rates of CAPZA2 promoter activity by overexpression 
of full-length and dominant-negative NRF-1s as well as PGC-1 are 
different between IMR-32 and HepG2 cells (Fig. 5-10). We confirmed the 
CAPZA2 were expressed in both IMR-32 and HepG2 cells (Fig. 1A). 
However, the mRNA levels of CAPZA2 in HepG2 cells were higher than 
that in IMR-32 cells. These results were consistent with that of promoter 
assays, suggesting less induction effects in HepG2 than in IMR-32 cells 
when overexpressing NRF-1s. According to these results, it suggests that 
involvement of NRF-1 in regulating CAPZA2 is cell-specific. 
4-4 Several transcription factors may involve in regulating CAPZA2 
expression  
 We compared core promoter sequences of the CAPZA2 gene of 
human, rat and mouse and found that the sequences of the NRF-1 sites are 
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identical among these three species (Fig. 12). This suggested that this site 
is evolutionarily important for the control of CAPZA2 gene expression. 
Moreover, there are several other conserved regions on the CAPZA2 
promoter of these three species, such as AP2, Sp1, Maz,...and so on. 
The promoter activity of -477 construct is about 25% higher than that 
of the -202 construct only in IMR-32 cells but not in HepG2 cells. This 
result suggests that this region contains cell-specific positive regulators 
for the CAPZA2 gene expressed in IMR-32 cells. On the other hand, the 
reporter constructs also revealed that there are negative regulators 
between -477 and -202 specific for HepG2 cells, because the promoter 
activity of the -477 construct is significantly decrease than that of the 
-202 construct in this cell line. This region -477/-202 may contain 
putative binding sites for NBF, ASCE element, NF-1/L, aba A, Myc-CF1, 
and ER. However, whether NBF, ASCE element, NF-1/L, aba A, 
Myc-CF1, and ER bind to this region is still unclear. What negative and 
positive regulators on CAPZA2 promoter are and whether NRF-1 can 
affect or mediate these putative regulators to coregulate or further 
regulate the expression of the CAPZA2 gene remain to be confirmed. 
4-5 CAPZA2 may not involve in neurite outgrowth 
In previous study, it has shown that NRF-1 can regulate neurite 
outgrowth through its downstream IAP gene (Chang et al., 2005). In this 
study, we demonstrated that NRF-1 regulates CAPZA2 gene expression. 
Therefore, we were curious whether CAPZA2 gene involve in neurite 
outgrowth and this process is mediated by NRF-1. First, we 
overexpressed CAPZA2 in human neuroblastma IMR-32 cells and then 
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observed the GFP-positive cells under fluorescence microscopy. However, 
we found that overexpression of CAPZA2 did not alter the percentages of 
cells bearing neurites as compared with the control pCMS-EGFP. 
According to this result, it suggests that CAPZA2 may not involve in 
neurite outgrowth. However, the involvement of CAPZA2 in neurite 
outgrowth is required further confirmation and different parameters, such 
as length of neurite, may need to be subjected to determine the functions 
of CAPZA2 in neurons. In addition, other methods to inhibit CAPZA2 
expression, such as RNAi or the CAPZA2 antisense cDNA, are useful 
tools for further confirming the role of CAPZA2 in neurite outgrowh. In 
addition, it may be necessary to determine whether transfected CAPZA2 
was expressed in IMR-32 cells by RT-PCR or Western blot and this 
exogenous protein is functional by actin polymerization assay. 
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CHAPTER 5 
CONCLUSION 
In conclusion, we have demonstrated that the core promoter of the 
human CAPZA2 gene is located between -477 and -42 nucleotides 
upstream of the translational initiation codon, and that NRF-1 is a critical 
transcription factor in regulating human CAPZA2 gene promoter. 
However, CAPZA2 may not involve in neurite outgrowth. Furthermore, 
NRF-1 coactivator PGC-1 also regulates the promoter activity of CAPZA2 
gene but it needs more experiments to clarify whether NRF-1 mediates 
this process. 
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Table 1. pGL3-CAPZA2 constructs and primer sequences for PCR 
reactions 
(1) pGL3-CAPZA2-1328
Forward: GGGGTACC CGCCTCTCGGGTTGCAATGACTTC
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(2) pGL3-CAPZA2-956
Forward: GGGGTACC TGCACCCATCACCTGAGCAGTGTA
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(3) pGL3-CAPZA2-477 
Forward: CAATTATGGAGAGGGTCGTGATGTG
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(4) pGL3-CAPZA2-202
Forward: GGCGCCCGCGCACGCGCACAG
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(5) pGL3-CAPZA2-180 
Forward: CGCGCTCAGTCCGCGAGGGCCG
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(6) pGL3-CAPZA2-141 
Forward: CTCCCGGGGTGCGCGTGCGCG
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(7) pGL3-CAPZA2-119 
Forward: CGGCCTGAGCGGCGGGCCCCTC
Reverse: ACGGAAACGGGGAAGTCAGGTGGC
(8) pGL3-CAPZA2-M1 
Forward: 
GGCCACCAGGCGCCCGCAAACGCAAACAGCCGCGCTCAGTCC
Reverse: 
GGACTGAGCGCGGCTGTTTGCGTTTGCGGGCGCCTGGTGGCC
(9) pGL3-CAPZA2-M2
Forward: GCGGGGCTCCCGGGGTTTGCGTTTGCGGCGGCCTGAGC
Reverse: GCTCAGGCCGCCGCAAACGCAAACCCCGGGAGCCCCGC
(10) pGL3-CAPZA2-M1+2 (pGL3-CAPZA2-M1 as template)
Forward: GCGGGGCTCCCGGGGTTTGCGTTTGCGGCGGCCTGAGC
Reverse: GCTCAGGCCGCCGCAAACGCAAACCCCGGGAGCCCCGC
 
 
 
 - 36 -
          
 
 
 
 
 - 37 -
         
 
         
 
FIG. 1. Identification of the core promoter region of the human 
CAPZA2 gene in IMR-32 and HepG2 cells. A, Expression of the human 
CAPZA2 gene in IMR-32 and HepG2 cells. B, promoter constructs. The 
restriction map of the 5’-flanking region of the human CAPZA2 gene is 
shown at the top. Positions are indicated relative to the translational 
initiation codon. The promoter constructs are named by the left boundary 
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and have a common 3’-end at -42. C and D, luciferase activity of the 
promoter constructs in IMR-32 and HepG2 cells. Two hundred fifty 
nanograms of independent constructs and pRL-TK plasmids were 
cotransfected into cells by the calcium phosphate precipitation method. 
The firefly luciferase activity after 14-16 h incubation was normalized to 
Renilla luciferase activity, which is as a transfection control. These values 
were then normalized to those of pGL3-Basic vector without any insert. 
Note the different scales of the x-axes in C and D. Values are presented as 
the mean ± S.E. obtained from three independent experiments, each 
conducted with triplicate cultures. *, p < 0.05; **, p < 0.01; ***, p < 
0.001; unpaired Student’s t test.  
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-477               CAATTAT GGAGAGGGTC GTGATGTGTA TTTTAATGAA
-440 AGCCAACTAT CTTCTCTAAT ATTTGAAAAA ACAATGTTTA AAAGGCTTCT
-390 ATTTGTACAC CTTTTCACAT TTTAGCTGGC AGAGTTCAGG ACTTGATGGA
-340 AACATAACGA AGGGCTCAGA ATGTACTCAT CGCAGACTGA GCCCATATGG
-290 TCACAGTGGG GAGAGCACGC TGCACTCAAG ATGCTAGCAA GCCTGCAGCA
-240 GGCGGCCCAG CGAGACACGG TCCCCCGCCC GGCCACCAGG CGCCCGCGCA
-190 CGCGCACAGC CGCGCTCAGT CCGCGAGGGC CGGGTCGAGG GAGGCGGGGC
-140 TCCCGGGGTG CGCGTGCGCG GCGGCCTGAG CGGCGGGCCC CTCCCTTAGC
-90  GGGGGCGCGC GGCGCTGAGG ACCGCACGGA AACGGGGAAG TCAGGTGGCC
-40  GCTGCCGCCG CCGCCGCCGC GGTTTGTCGC CAGAAGGAAG ATGGCGGA 
Sp1Ap2 NRF-1
Sp1
NRF-1 Sp1 Ap2Ap2
 
 
FIG. 2. The sequence of 5’-flanking region of the human CAPZA2 
gene. The sequence spanning from -477 to the translational initiation 
codon ATG is shown. This region contains putative binding sites for 
transcription factors such as AP-2, Sp1, and NRF-1. The positions of 
these sites are indicated by underlines. The plasmids for the luciferase 
assay were constructed by inserting fragments spanning from nucleotides 
(indicated by arrows) to nt -42, relative to ATG, into the firefly luciferase 
expression vector (pGL3-Basic). 
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FIG. 3. Identification of NRF-1 site in the CAPZA2 core 
promoter. Mutant constructs were made by site-directed  
mutagenesis (the pGL3-477M1, pGL3-477M2, and pGL3-477M1+2 
constructs). The putative NRF-1 sites are indicated in upper panel. 
Independent constructs and pRL-TK plasmids were cotransfected into 
IMR-32 (A) and HepG2 (B) cells using the same protocol as shown in Fig. 
1. The promoter activity was expressed with respect to the -477 construct. 
*, p < 0.05; ***, p < 0.001; unpaired Student’s t test. 
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FIG. 4. Electrophoretic mobility shift analysis of the NRF-1 binding 
activity in IMR-32 cells. These two NRF-1 sites of CAPZA2 promoter 
are localized at -196/-185 (termed CAPZA2-1) and -132/-121 (termed 
CAPZA2-2). Band shift analysis of the NRF-1 binding activity. Three 
micrograms of nuclear extracts were incubated with the CAPZA2 NRF-1 
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oligonucleotides labeled by the 32P fill-in method at 4 °C for 30 min and 
then electrophoresed on a 4% Tris borate-EDTA polyacrylamide gel. 
Mixtures containing no nuclear extract were used as negative controls. 
Supershift analysis using the NRF-1 antibody. Antibodies were incubated 
with 3 µg of nuclear extracts prior to the addition of the CAPZA2 NRF-1 
probes. The anti-NF-κB and normal goat serum were used as negative 
controls. Arrows indicate the shifted and supershifted bands as well as 
free probe. 
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FIG. 5. Overexpression of the NRF-1 increases the CAPZA2 promoter 
activity in IMR-32 and HepG2 cells. A, RT-PCR showed different 
expression levels of exogenous full-length or dominant-negative NRF-1. 
B and C, Various amounts (100-1000 ng) of the full-length NRF-1 
construct or 1000 ng of the empty vector were transiently cotransfected 
with 250 ng of pGL3-477 into cells. After transfection, IMR-32 and 
HepG2 cells were cultured for 14-16 h, respectively. The relative activity 
was plotted as percentages of the firefly luciferase activity of the mock 
control. Values are presented as mean ± S.E. *, p < 0.05; **, p < 0.01; 
***, p < 0.001; unpaired Student’s t test. 
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FIG. 6. Overexpression of the dominant-negative NRF-1 decreases the 
CAPZA2 promoter activity in IMR-32 and HepG2 cells. Various 
amounts (100-1000 ng) of the dominant-negative NRF-1 construct or 
1000 ng of the empty vector were transiently cotransfected with 250 ng of 
pGL3-477 and 250 ng of pRL-TK into cells. After transfection, IMR-32 
and HepG2 cells were cultured for 14-16 h, respectively. The relative 
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activity was plotted as described previously. Values are presented as the 
mean ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001; unpaired Student’s t 
test. 
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FIG. 7. Mutation of putative NRF-1 binding sites influences 
full-length NRF-1-induced CAPZA2 promoter activity in IMR-32 and 
HepG2 cells. Five hundred nanograms of the full-length NRF-1 construct 
or 500 ng of the empty vector were transiently cotransfected with 250 ng 
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of pGL3-477 (wild type) or pGL3-477M1, pGL3-477M2 and 
pGL3-477M1+2 and 250 ng of pRL-TK into cells. After transfection, 
IMR-32 and HepG2 cells were cultured for 14-16 h. The relative activity 
was plotted as described previously. Values are presented as the mean ± 
S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001; unpaired Student’s t test. 
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FIG. 8. Mutation of putative NRF-1 binding sites influences 
dominant-negative NRF-1-induced CAPZA2 promoter activity in 
IMR-32 and HepG2 cells. Amount (100 ng) of the dominant-negative 
NRF-1 construct or 100 ng of the empty vector were transiently 
 - 51 -
cotransfected with 250 ng of pGL3-477 (wild type) or pGL3-477M1, 
pGL3-477M2 and pGL3-477M1+2 and 250 ng of pRL-TK into cells. 
After transfection, IMR-32 and HepG2 cells were cultured for 14-16 h. 
The relative activity was plotted as described previously. Values are 
presented as the mean ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001; 
unpaired Student’s t test. 
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FIG. 9. Overexpression of the PGC-1 regulates the CAPZA2 promoter 
activity in IMR-32 and HepG2 cells. Various amounts (100-1000 ng) of 
the PGC-1 construct or 1000 ng of the empty vector were transiently 
cotransfected with 250 ng of pGL3-477 and 250 ng of pRL-TK into cells. 
After transfection, IMR-32 and HepG2 cells were cultured for 14-16 h. 
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The relative activity was plotted as described previously. Values are 
presented as the mean ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001; 
unpaired Student’s t test. 
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FIG. 10. Mutation of putative NRF-1 binding sites influences 
PGC-1-induced CAPZA2 promoter activity in IMR-32 and HepG2 
cells. Five hundred nanograms of the PGC-1 construct and the empty 
vector were transiently cotransfected with 250 ng of pGL3-477 (wild type) 
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or pGL3-477M1, pGL3-477M2 or pGL3-477M1+2 and 250 ng of 
pRL-TK into cells. After transfection, IMR-32 and HepG2 cells were 
cultured for 14-16 h. The relative activity was plotted as described 
previously. Values are presented as the mean ± S.E. *, p < 0.05; **, p < 
0.01; ***, p < 0.001; unpaired Student’s t test. 
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FIG. 11. Overexpression of CAPZA2 does not affect neurite 
outgrowth in IMR-32 cells. IMR-32 cells were transfected with 
GFP-empty vector (1 µg), vector containing CAPZA2 cDNA (1 µg) or 
full-length NRF-1 cDNA (1 µg) for 14-16 h. After transfection, cells were 
cultured for 1-3 days in the medium containing 10% FBS medium. 
GFP-positive cells were observed under a fluorescent microscope. After 
transfection, cells carrying extended neurites (>25 µm) were counted. 
Values are averages of three counts on more than 100 GFP-positive cells. 
*, p < 0.05; **, p < 0.01; ***, p < 0.001; unpaired t test. 
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Mouse      TATATCAAAAGTAATCTTTCAATTATGGACTGGATTGTGTGTGCCTATTTCAATTAAAAC -486 
Rat        ........A..T.................CT..A.T...TG..CC.....T...T...A. -474 
Human      ........G..C.................GA..G.C...-A..TG.....T...G...G. -438 
 
 
 
Mouse      --AGTATTTTTCCTAATACTTA....-----TGTTTTAAA--------TTGGTACAGCTT -441 
Rat        --.G...T..TC......C..A....-----.....T...--------..G.....G... -429 
Human      CA.C...C..CT......T..G....AACAA.....A...GGCTTCTA..T.....C... -378 
 
 
 
Mouse      TTCACATTTTA-GCTGGCAGCGTTCAGGACTTGGTGGGAACAAAGTCATGGGCTCAGAAT -382 
Rat        ..........TT.T......C............G...G....A.GTC.T........... -369 
Human      ..........A-.C......A............A...A....T.ACG.A........... -319 
 
 
 
Mouse      GTACTCATCGCCAACCGGGTCCATATGGTCATCGTTGACTAGAGAAGGCACCAGACAGAG -322 
Rat        ...........CA..CTG.T...........T.AT..GGT....A.G..AC..G----.. -313 
Human      ...........AG..TGA.C...........-.AG..GGG....C.C..TG..CTCA-.. -261 
 
 
 
Human      ATGCTAGCAAGCCTGCAGCAGGCGGCCCAGCGAGACACGGTCCCCCGCCCGGC------- -208 
 
Mouse      AGGATGACAGAAGATAACCATAGCAATCCCACTTTGGAGGCG-CTGCGCACGCGCACAGC -263 
Rat        AGGATGACAGAAGATA-CCATAG..AT..GACTTTGG.....-.T..............T -255 
Human      -----------------------..--..--------.....C.C..............- -182 
 
 
 
Mouse      GGCGCTCAGGCCGGCGCTCAGGGGGAGGGAGGCGGAGCTCCGGGGGCGCGTGCGCGGCGG -203 
Rat        GGCGCTCAGGCCTGCGATCAGGGG-AGGGAGGCGGAGCTCTGGGG-CGCGTGCGCGG.G. -197 
Human      ---------------------------------------------------------.C. -179 
 
 
 
Mouse      CCTAGGCTGAGGAGGCGGAGCTCCCAGGCGTGTGCGCAGTGGCTCGGCTCCCGGGAGGCG -143 
Rat        .TTGAG--GA--AGGCGGA....CCGGGCGT..G...AGT...TT..A..C-........ -142 
Human      .------------------....A-------..C...GAG...-C..G..GA........ -145 
 
 
 
Mouse      GAGCTCC---GGGGCGCGTGCGCGGCGGCCTGGGCGGCGGGGCCCCTCCCTTGGCGGGGG -86 
Rat        .A.....---..G...................G........-..........G....... -86 
Human      .G.....CGG..T...................A........-..........A....... -86 
 
 
 
Mouse      CGCGCGGCGCGGAAGACCGCTCGGAAAGGGGGAAGTCAGGTGGCCGCTGCTGCCACCAGC -26 
Rat        ..........G..A......A......G......................T...A..AG. -26 
Human      ..........T..G......A......C......................C...G..GC. -26 
 
 
 
Mouse      GCCACGGTCTGTCGCCAGAAGGAAGATGGCGGATCTGGAGGAGCAGTTGTCCGATGAGGA  35 
Rat        ...A....T..........................................C.....G..  35 
Human      ...G....T..........................................T.....A..  35 
 
 
 
NBF
ASCE2 element NF-1/L aba A
ER
SP-1
AP-2
Myc-CF1
NRF-1
NRF-1 SP-1 MAZ
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FIG. 12. Conservation of the NRF-1 sites in the human, mouse, and 
rat CAPZA2 genes. The mouse sequence is shown in its entirety. Bases 
in the sequence of human and rat that are identical to the mouse sequence 
are shown as dots, with only those bases that differ from the mouse 
sequence identified. The regions containing AP-2, Maz, NBF, ASCE2 
element, NF-1/L, aba A, Myc-CF1, ER, Sp1, and NRF-1 binding sites 
(underlines) are highly conserved in these three species. The missing 
bases are marked by “-“. The numbers are relative to the translational 
initiation codon. 
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